4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics Summit
October 12 2021 - 06:00AM
Business Wire
4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical
company leading the development of Live Biotherapeutic products
(LBPs), a novel class of drug derived from the microbiome, today
announces that 4D management will present at the Jefferies Virtual
Next Generation IBD Therapeutics Summit being held on October 19,
2021.
A webcast of the presentation will be available on the ‘Events’
section of the 4D pharma website at www.4dpharmaplc.com beginning
Tuesday, October 19, 2021 at 8:00 a.m. ET (1:00 p.m. BST).
About 4D pharma
4D pharma is a world leader in the development of Live
Biotherapeutics, a novel and emerging class of drugs, defined by
the FDA as biological products that contain a live organism, such
as a bacterium, that is applicable to the prevention, treatment or
cure of a disease. 4D has developed a proprietary platform,
MicroRx®, that rationally identifies Live Biotherapeutics based on
a deep understanding of function and mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has five clinical programs,
namely a Phase I/II study of MRx0518 in combination with KEYTRUDA
(pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumors, a Phase I study
of MRx0518 in patients with pancreatic cancer, a Phase I/II study
of MRx-4DP0004 in asthma, and Blautix® in Irritable Bowel Syndrome
(IBS) which has completed a successful Phase II trial.
Preclinical-stage programs include candidates for CNS disease such
as Parkinson's disease and other neurodegenerative conditions. The
Company has a research collaboration with MSD, a tradename of Merck
& Co., Inc., Kenilworth, NJ, USA, to discover and develop Live
Biotherapeutics for vaccines.
For more information, refer to https://www.4dpharmaplc.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211012005054/en/
4D pharma Investor Relations: ir@4dpharmaplc.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496
3000 Philip Davies / Iqra Amin / James Fischer (Corporate Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332
2500 Dominic Wilson / Phil Walker
Stern Investor Relations, Inc. +1-212-362-1200 Julie Seidel
Julie.seidel@sternir.com
Image Box Communications +44 (0)20 8943 4685 Neil Hunter /
Michelle Boxall neil@ibcomms.agency / michelle@ibcomms.agency
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Feb 2024 to Mar 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2023 to Mar 2024